Stem Cell News: Breaking Stem Cell News, Comments and Articles.

CA BOTANA International Introduces New Peptide Formulations

SAN DIEGO, May 21, 2013 /PRNewswire/ -- CA BOTANA International has created several novel peptide formulations that improve the skin's ability to defy aging, and that provide a more youthful, vibrant appearance to the skin. (Logo: http://photos.prnewswire.com/prnh/20130517/AQ16286LOGO) Bioactive peptides of high purity (>95%) and proven efficacy in vivo are incorporated into CA BOTANA's for...

Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research

New data from the National Health and Wellness Survey show the effects of non-adherence on outcomes of patients with leukemia, melanoma or non-small cell lung cancer. New York, NY (PRWEB) May 21, 2013 Two-thirds of patients who have been diagnosed with leukemia, melanoma or non-small cell lung cancer reported that they engage in at least one type of non-adherent behavior in their medicine use, ac...

Proteostasis Therapeutics Presents Preclinical Data on Parkinson’s Disease and Cystic Fibrosis Targets at EMBO Conference

Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, today presented data on the Company’s preclinical targets for Parkinson’s disease and cystic fibrosis at a conference hosted by the European Molecular Biology Organizatio...

CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors

Aldoxorubicin shows prolonged clinical activity in two clinical trial patients with small cell lung cancer who have failed other therapies Data show that aldoxorubicin demonstrates a significant 250-fold lower distribution to healthy tissue compared with doxorubicin CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and deve...

American Cancer Society to Recognize Industry Leaders at Annual Financial Services Cares Gala

-- Gala will take place Monday, June 24, 2013, at Cipriani 42nd Street, New York (Register here: http://cog.to/14eXevw) -- Eighth annual event will honor Dr. Andrew L. Kung and PIMCO for their continued commitment to cancer awareness and research The American Cancer Society announced today it will be hosting the

Babak Larian, MD, FACS Discusses New Study Regarding Radiotherapy in Early-Stage Parotid Acinic Cell Cancer

Dr. Babak Larian, Otolaryngologist in Beverly Hills, says that radiotherapy may not be a helpful treatment option for patients experiencing early-stage parotid acinic cell cancer. Beverly Hills, CA (PRWEB) May 21, 2013 Babak Larian, MD, FACS, in Beverly Hills agrees with the latest study regarding radiotherapy and it’s uses in the treatment of early stage parotid acinic cell cancer. According t...

BioRestorative signs consulting agreement with Dexterity for stem cell therapy device

BioRestorative Therapies (BRT) has signed a consulting agreement with Dexterity, to develop and manufacture BRT's proprietary therapeutic delivery device for its intervertebral disc stem cell therapy program, brtxDISC (Disc Implanted Stem Cells).

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

USA-based Cell Therapeutics (Nasdaq: CTIC) says that Germany's Federal Joint Committee (G-BA) has issued its final benefit assessment report for Pixuvri (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggres...

Maryland Stem Cell Research Commission Funds 31 New Research Proposals in FY 2013

COLUMBIA, Md., May 21, 2013 /PRNewswire/ -- The Maryland Stem Cell Research Commission (Commission) has completed its review of the 171 applications received in response to its FY 2013 Requests for Applications (RFAs). The board of directors of the Maryland Technology Development Corporation (TEDCO) approved the Commission's recommendation to fund 31 new proposals with the Maryland Stem Cell...

Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors

NORTH BRUNSWICK, N.J., May 21, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of James S. MacDonald, PhD, DABT to the Company's Board of Directors. Dr. MacDonald is the former Executive Vice President of Preclinical Development of the Schering-Plough Res...

Lehigh Valley Expands Fleet of Superbug-Slaying Robots

ALLENTOWN, Pa., May 21, 2013 /PRNewswire/ -- Lehigh Valley Health Network has announced the deployment of two additional TRU-D SmartUVCTM devices, adding to its existing arsenal of five 5-foot-5 germ-killing UV disinfection robots. With seven devices taking up residence within the network, LVHN is now deploying the largest fleet of TRU-Ds in the U.S. to proactively combat superbugs...

Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine

PARIS and TARRYTOWN, N.Y., May 21, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine published online the positive Phase 2a study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe allergic asthma.  Dupilumab is an investigational monoclonal antibody ta...

Neuralstem: Update On Phase I Trial Of Neural Stem Cells In ALS Is Encouraging

By Smith On Stocks: Purpose of Report An encouraging update on the Phase I trial of Neuralstem's (CUR) neural stem cells in ALS was just presented. I alerted investors about this potential catalyst in my recent blog. Investment Conclusion Before I state my conclusions, let me quote the lead investigator on the study, Dr. Eva Feldman. She said "Collectively, these preliminary results suggest th...

Without Glia, the Brain Would Starve

The brain is voracious: compared with other organs, it consumes 10 times more oxygen and nutrients, receiving them by way of dense networks of blood vessels. Scientists know how these networks initially grow, but a surprising new study suggests that...

Complix to Present at Upcoming BioEquity Europe 2013

HASSELT, Belgium, May 21, 2013 /PRNewswire/ -- Complix, a biopharmaceutical company focused on the discovery and development of Alphabodies™, a unique class of protein therapeutics that are active against intracellular disease targets, announces that its CEO Dr Mark Vaeck will present at BioEquity Europe 2013 in Stockholm, Sweden (May 22nd-23rd). Details of the presentation are listed below...

MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutic...

BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference

JUPITER, Fla., May 21, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX), a life sciences company focused on developing stem cell based therapies for various personal applications, announced that Mark Weinreb, its President and CEO, will be presenting at the Marcum MicroCap Conference.   The conference will be held on Thursday, May 30, 201...

Cell Therapy Catapult releases preclinical database

Cell Therapy Catapult releases preclinical database

Elbit Imaging Announces Receipt of Notices from Bank Leumi - Update

TEL AVIV, Israel, May 21, 2013 /PRNewswire/ -- Elbit Imaging Ltd. ("EI" or the "Company") (TASE, NASDAQ: EMITF) announced today, further to the Company's announcement dated March 20, 2013, that it has received a notice from Bank Leumi le-Israel B.M. (the "Bank"), which the Company vigorously reject, stating that the Bank plans to exercise its rights to withdraw the securities deposited by the Com...

Promoting STEM Education, Foolishly

Here's a man who says what he thinks about getting students into STEM careers: The United States spent more than US$3 billion last year across 209 federal programmes intended to lure young people into careers in science, technology, engineering and...

Post America Depression

Dr. Shinya Yamanaka won the 2012 Nobel Prize for Physiology or Medicine, for his 2006-2007 work on induced pluripotent stem cells. I had a chance to hear him talk at the A*STAR Biopolis complex in April, where he gave a lecture on the recent progress in induced pluripotent stem (iPS) cell research. But at a smaller, 13-member session at Biopolis complex, he also spoke candidly with budding young s...

Merck Millipore, PharmaCell to Optimize Cell Harvesting Using Bioreactor Technology

The project is expected to deliver scalable expansion and harvesting devices, validation methods and associated protocols for the production of large-scale stem cell therapies.

Phase III Trial Of L-BLP25 In Patients With Non-Small Cell Lung Cancer (START) - Primary Endpoint Of Significantly Improving Overall Survival Not Met

Confirmed: Primary endpoint of significantly improving overall survival not met Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomized Phase III START* trial of its investigational MUC1 antigen-spe...

During CA Pertussis Outbreak, Whole-Cell Vaccine More Effective Than Acellular Vaccine

Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics. Whole-cell pertussis vaccines, als...

Outcome In Head And Neck Cancer Predicted By Genetic Diversity Within Tumors

A new measure of the heterogeneity - the variety of genetic mutations - of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, investigat...